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Abstract Much of our current understanding of the path-
ogenic mechanisms in human neurodegenerative disorders
has been derived from animal studies. As such, transgenic
mouse models have signiWcantly contributed to the devel-
opment of novel pathogenic concepts underlying human
tauopathies, a group of diseases comprising various forms
of neurodegenerative disorders including Alzheimer’s dis-
ease, corticobasal degeneration, argyrophilic grain disease,
progressive supranuclear palsy, and Pick’s disease as well
as hereditary fronto-temporal dementia with parkinsonism
linked to chromosome 17. Here, we will review in vivo
models of human tauopathies with particular preference to
transgenic mouse models. Strengths and limitations of these
models in recapitulating the complex pathogenesis of tau-
opathies will be discussed.
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Introduction
Pathologic alterations in the microtubule-associated protein
tau have been linked to the pathogenesis of a number of
neurodegenerative disorders, including Alzheimer’s disease
(AD), progressive supranuclear palsy (PSP), corticobasal
degeneration (CBD), argyrophilic grain disease (AgD),
Pick’s disease (PD), as well as a subset of hereditary
frontotemporal dementias (FTDs), which are therefore also
collectively classiWed as tauopathies [24, 49, 87]. In these
diseases, the microtubule-associated protein tau accumu-
lates, forming detergent-resistant intracellular inclusions
known as neuroWbrillary tangles (NFTs). In AD, the tempo-
ral and spatial distribution of tau pathology correlates well
with the clinical disease severity [9]. However, whether it
acts as the primary culprit or is indirectly involved in the
pathogenic pathways culminating in neuronal cell loss, is
still hotly contested. Although pathogenic tau mutations
have been identiWed in FTD with parkinsonism linked to
chromosome 17 (FTDP-17T) which is clear evidence of tau
dysfunction playing a pivotal role in neurodegeneration, the
mechanism of tau dysfunction leading to neuronal demise
is only poorly understood.
In many ways, human tauopathies represent a heteroge-
neous group of diseases, with aVected patients presenting
with diverse clinico-pathological phenotypes ranging from
prototypical aphasia to dementia syndromes. It is therefore
of utmost importance to elucidate the mechanisms of tau
accumulation and NFT formation in these diseases, and in
particular to answer the question of whether all tauopathies
develop through a unifying common pathogenic pathway.
On the molecular level, the phenotypic diversity of tauopa-
thies is attributable to diVerent types of tau gene mutations
as well as additional modifying genetic and epigenetic fac-
tors. Whereas on the cellular level, not only neuronal but
also glial cell elements can be aVected by tau-related
pathology in locoregionally diVerent and disease- (and
sometimes also stage-) speciWc patterns, heterogeneity on
the biochemical level is reXected by the expression of
diVerent tau isoforms. These isoforms arise through alterna-
tive splicing, yielding variants with diVerential binding to
microtubules according to the presence of either three (3R
isoforms) or four microtubule-binding repeat domains (4R
isoforms). Homologous repeat sequences are also present in
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a major microtubule-associated protein, mammalian tau is
subject to extensive regulation on the transcriptional level
and to post-translational modiWcation, in particular to phos-
phorylation, resulting in complex biochemical patterns
[51]. Through binding to microtubules, tau is involved in
the initiation and stabilization of these structures, which, in
neurons, are critical for axonal transport and proper synap-
tic function [84]. Of particular note, overexpression of tau
in neuronal cell lines as well as in primary neurons leads to
disturbed kinesin-dependent traYcking of organelles along
microtubule tracts [21, 86]. In particular, mitochondria fail
to be transported to peripheral cell compartments, which
may represent an important pathogenic mechanism for neu-
rodegeneration [79], contributing to the loss of synapses as
an early event in AD pathogenesis [14, 83].
In the adult human brain, six tau isoforms are expressed
that are generated through alternative splicing [12, 23, 49].
These isoforms diVer by containing either three or four
microtubule-binding domains within their C-termini (3R
and 4R isoforms, respectively) with additional variability
arising from the existence of none, one or two N-terminal
inserts (0N, 1N, 2N isoforms). The 4R isoforms bind to
microtubules more avidly than the 3R variants. Isoform
expression patterns are developmentally regulated with the
3R variants being expressed during early life phases (“fetal
tau”) and it has therefore been hypothesized that expression
of 3R tau might be associated with the higher degree of
plasticity that is required during neuronal development
[26]. Although in embryonic hippocampal slice cultures of
tau-null mice an inhibition of neuronal maturation can be
demonstrated [19], tau-deWcient mice appear physiologi-
cally normal, are able to reproduce and do not develop
obvious neurological phenotypes, presumably because
other microtubule-associated proteins (such as MAP1A and
1B) can compensate for tau loss [31].
For quite some time, interest in tau as an important path-
ogenic factor in AD-related neurodegeneration has lagged
behind the research eVorts devoted to the amyloid beta pep-
tide (A), partly because tau pathology was commonly
accepted to occur downstream of A according to the beta
amyloid cascade hypothesis [32]. However, in various
other tauopathies, prominent tau pathology develops in the
absence of extracellular A deposits. In addition, the identi-
Wcation of tau mutations underlying the pathogenesis of
FTDP-17T [39, 68, 75], a neurodegenerative FTD entity
which follows an autosomal-dominant mode of inheritance,
has sparked intense research eVorts aimed at the generation
of animal models not only to decipher the role of tau in neu-
rodegeneration but also at deriving novel therapeutic
approaches for human tauopathies.
Remarkably, several crucial features of human tauopa-
thies have been recapitulated in relatively simple organisms,
such as Caenorhabditis elegans and Drosophila melanog-
aster. However, in these models many pathogenic aspects
are overly simpliWed and therefore considerably limit the
interpretation of Wndings in terms of drawing parallels to
the pathogenic pathways at play in human tauopathies.
Consequently, various tau transgenic (tg) mouse lines have
been generated to closer model aspects of the very com-
plex, multi-facet pathogenesis of human tauopathies. After
brieXy summarizing selected Wndings in C. elegans and D.
melanogaster, we will focus this review on the various tg
mouse models that have been generated to experimentally
recapitulate important histopathological, and sometimes
also behavioral features of tauopathies.
Modeling tauopathies in C. elegans
Caenorhabditis elegans represents an easy to genetically
manipulate model for the experimental characterization of
normal gene function as well as for exploring pathogenic
protein dysfunction. To model tauopathy disorders, sev-
eral transgenic worm models have been generated [10, 46,
61]. Neuronal expression of normal and FTDP-17T asso-
ciated mutant human tau proteins (P301L, V337M) [46]
caused progressive uncoordinated locomotion, indicative
of a nervous system defect, which culminated on day 9
with worms becoming nearly immobile. Moreover,
expression of wildtype (wt) human tau was associated
with a decreased life span [46]. Interestingly, the trans-
genic tau protein expressed in C. elegans was found to be
phosphorylated at analogous residues as it occurs in
human tauopathies [46], an observation recently con-
Wrmed independently [10]. Of note, whereas no neuronal
degeneration was reported by the latter group, transgenic
human tau was demonstrated to become highly phosphor-
ylated and to assume a PHF-like conformation [10]. Sig-
niWcantly, FTDP-17T mutant tau lines exhibit a more
severe phenotype marked by the production of more
detergent-insoluble tau and by a more severe axonal
degeneration in comparison to wt-tau expressing lines
[46]. In particular, in the line expressing the FTDP-17T-
associated V337M tau mutation, the high level of insolu-
ble tau was paralleled by extensive axonal degeneration
[46]. Nerve cell degeneration, accompanied by tau-accu-
mulation in cell bodies and neuronal processes, was
recently also reported for another transgenic worm model
where the P301L and R406W mutations were expressed
in mechanosensory neurons [61]. Thus, the induced tau
pathology in worms resembles the situation in human tau-
opathies in so far as there is progressive accumulation of
hyperphosphorylated insoluble tau as well as neurodegen-
eration with one of the main diVerences being the absence
of overt tau tangle formation in C. elegans. Nevertheless,123
Acta Neuropathol (2008) 115:39–53 41in summary, these experiments provided evidence for at
least a contributory (if not primary causal) role of tau in
neurodegenerative processes and thus points to a high
degree of evolutionary conservation in tau-associated
pathogenesis.
Lessons from Drosophila
Bridging the simplicity of C. elegans and the complexity
of vertebrate models, D. melanogaster has become an
invaluable tool for the study of neurodegenerative dis-
eases [6]. At least 50% of Drosophila genes have human
homologs and more than 70% of human disease genes
have Drosophila homologs, making the (rather primitive)
Xy a relevant organism to model selected aspects of
human diseases, including neurodegenerative disorders.
Drosophila Xies possess one single tau gene, which is
expressed in many types of neurons, where in analogy to
mammalian neuronal cells, tau protein can also accumu-
late within axonal processes [33]. Wittmann et al. [95]
have generated transgenic D. melanogaster Xies as a
genetic model of tau-associated neurodegenerative disor-
ders by expressing wt and mutant (R406W, V337M)
forms of human tau which recapitulated key features of
human tauopathies. Despite only moderate levels of trans-
gene expression, transgenic Xies exhibited adult onset
progressive neurodegeneration with a signiWcantly
reduced life span, especially in the R406W tg Xy lines.
With relative anatomic selectivity abnormal tau protein
accumulated, but NFT formation was not observed. In
summary, these results indicated that tau-induced neu-
rodegeneration in Xies does occur in the absence of large
tau Wlamentous aggregates [95]. Moreover, overexpres-
sion of the human tau homolog in Drosophila neurons
induces apoptosis, which is not accompanied by the for-
mation of intracellular NFTs [6, 22, 43]. This Wnding,
which, prima vista, would argue against a signiWcant
cytotoxic role of tau-rich NFTs, could reXect a mode of
neurotoxicity which depends on protein alterations occur-
ring prior to the assembly of Wbrillar aggregates such as
on smaller proteolytic tau fragments, which—at least in
the human system—were recently postulated to be patho-
genically important by promoting aggregation through
nucleation eVects [50, 67, 93]. However, when wt human
tau (4R isoform) was coexpressed with the Xy homolog of
glycogen synthase kinase-3beta (one of the known tau-
phosphorylating kinases) in another Drosophila model,
NFTs were observed [43]. Thus, Drosophila tau models
may faithfully replicate several important aspects of
human tauopathies, including tau hyperphosphorylation,
accumulation, and Wbril formation as well as neuronal
degeneration.
Mouse models
A considerable number of mouse tauopathy models have
been generated that not only recapitulated key histopatho-
logical hallmarks of tauopathies but, to a variable degree,
also reproduced important behavioral aspects of the respec-
tive human disorders. Tauopathies are morphologically het-
erogeneous disorders, with neuronal and/or glial cell
components aVected in rather disease-speciWc and some-
times stereotypic spatiotemporal patterns [24, 49, 87]. On
the molecular level, it should be noted, that in contrast to
the adult human brain only 4R variants of the murine tau
homolog are endogenously expressed in the adult mouse
brain. Furthermore, major AD-related phosphorylation sites
of human tau are conserved in the murine protein, including
those phosphorylated by the major tau kinases glycogen
synthase-kinase 3 (GSK-3) and cyclin-dependent kinase
5 (CDK5), both of which also serve crucial roles during
neurodevelopment [16, 17, 44]. Of note, with regard to AD
pathogenesis, -amyloid has been shown to trigger tau
phosphorylation by activating GSK-3 and CDK5 [44, 48].
It therefore seems that the mouse lends itself as a model
organism to recapitulate essential aspects of tauopathies.
However, as will be discussed below, extreme care needs to
be exercised in the interpretation of histopathological Wnd-
ings and the results of behavioral tests. Depending on the
promoter system chosen to drive transgene expression, the
phenotypes of tg mouse models often diVer strikingly even
if the very same transgene is expressed. Whereas, the
murine thy-1 promoter favors transgene expression espe-
cially in brain stem and spinal cord (which consequently
often results in an axonopathy-related pathology through
the preferential aVection of the long Wber tracts), others
such as the -calcium-calmodulin-dependent kinase-II
(CaMK-II) promoter target expression predominantly to the
forebrain giving rise to behavioral phenotypes. In addition,
gene dosage eVects and altered ratios of expressed tau iso-
forms (i.e., 4R versus 3R variants) have to be taken into
account. Furthermore, through the use of additional pro-
moters, cell-type speciWc transgene expression (neuronal
versus glial expression) can be achieved. Moreover, diVer-
ent promoters yield variable transgene expression levels,
which is extremely relevant as pathological protein aggre-
gation including the assembly of Wbrillar protein deposits is
concentration-dependent. Last but not least, as will be dis-
cussed in more detail below, phenotypes of tg mice show
striking variance depending on whether transgene expres-
sion occurs in the murine endogenous or in a knockout
background. Thus, currently existing tg mouse models can
only recapitulate selected aspects of human tauopathies.
With regard to the multiple molecular pathways that have
so far been implicated with the rather complex pathogenesis
of these diseases, it currently seems more than questionable123
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mirror the full human disease phenotypes will ever be
achieved. Rather, a more realistic view seems that by care-
fully putting together the single pieces of information that
are provided by each of the mouse models, a picture will
emerge in the hopefully not too distant future that permits
understanding the complex pathogenic pathways in tauopa-
thies well enough to devise rationale, eVective and possibly
individualized therapeutic approaches to combat these dev-
astating diseases.
Models with tg expression of human wt tau isoforms 
(Table 1)
Modeling neuronal pathology
The initial mouse models for human tauopathies allowed
only speciWc human tau isoforms to be studied within the
background of endogenous wt murine tau. The Wrst tg
mouse models were generated more than a decade ago,
when pathogenic tau mutations had not yet been identiWed,
by expressing the longest human brain tau isoform (4R/2N)
under the control of the human thy-1 promoter [29]. The tg
human tau protein was found to be expressed in neuronal
cell bodies, axons and dendrites. Interestingly, the tg tau
protein, expressed at rather low levels, was phosphorylated
at the same sites that are hyperphosphorylated in the paired
helical Wlaments in human AD brains. In the absence of
NFTs this observed pathology [29] was therefore inter-
preted as a pre-tangle phenotype, to be considered as intra-
cellular “precursor” lesion preceding the full-blown tau
NFT pathology associated with tauopathies [3, 8]. In a sim-
ilar mouse model where the human 4R/2N isoform was
expressed under the control of the murine thy1 (thy-1.2,
respectively) promoter, prominent somatodendritic tau
expression and hyperphosphorylation was demonstrated
[69, 77] (Fig. 1a, b). These mice exhibited severe axonopa-
thy with signs of Wallerian degeneration reXected by
axonal breakdown and myelin sheath disintegration. More-
over, severe motor symptoms with neurogenic hindleg
muscle atrophy, as histologically veriWed by the presence of
grouped small angular muscle Wbers, developed in these
animals [69, 77].
In further models, alternative promoters such as the one
for mouse prion protein (MoPrP) were used to control
transgene expression which resulted in even more pro-
nounced phenotypes. Two tg models, in which the shortest
human brain isoform of tau (3R/0N) was expressed, were
created [11, 41]. Brion et al. [11], using a mouse model
with rather low 3R tau transgene expression driven by the
murine, house-keeping type HMG-CoA-reductase promoter,
did not Wnd NFTs in mice younger than 19 months of age,
but the tg protein was demonstrated to be phosphorylated
at sites known from tau proteins of paired helical Wlaments.
In contrast, using the MoPrP promoter to drive transgene
expression, insoluble, hyperphosphorylated tau progres-
sively accumulated and NFT-like argyrophilic intraneuro-
nal inclusions consisting of tau-immunoreactive Wlaments
were observed in these mice as early as at 6 months of age
[41]. Due to high-transgene expression in spinal cord motor
neurons, variable axonopathy with formation of tau-immu-
noreactive spheroids and histomorphological correlates of
axonal degeneration was found. Of note, the tau inclusions,
although stainable by the Bodian silver method, were not
detectable by the Gallyas procedure, which detects most
NFTs in human tauopathies [90]. Nevertheless, although
formation of bona Wde NFTs was not observed (unless the
mice reached a very old age [42]), these were the Wrst tg
mice to recapitulate key features of human tauopathies. The
follow-up analysis of these mice at 12–24 months of age
[42] revealed that the Wbrillary tau lesions had now
converted into AD-like tangle structures detectable by the
Gallyas silver impregnation method. The particular relevance
of this model was that, for the Wrst time, an age-dependent
maturation of tau inclusions culminating in the assembly of
insoluble, Wlamentous, Gallyas-positive NFTs was experi-
mentally recapitulated.
As pointed out earlier, the interpretation of these mouse
models, while being valuable Wrst steps to explore the role
of tau in neurodegeneration, was restricted by the fact that
only one speciWc isoform of human tau was transgenically
expressed. To avoid this caveat, alternative novel mouse
models were created. DuV et al. [20] generated mice that
overexpressed a human tau transgene containing not only
the coding regions but also intronic as well as regulatory
sequences. Thus, in these mice, all six human tau isoforms
were expressed at the mRNA and protein level in the CNS
but when compared to human brain the ratio of 3R:4R
human tau isoforms diVered as relatively more 3R tau was
present in these mouse brains. However, due to the pres-
ence of 4R endogenous murine tau there was no imbalance
of the total 3R:4R ratio. Tau-positive axonal swellings
developed in the spinal cords of the mice and correlated
with a hind-limb abnormality, but no other neuropathologi-
cal abnormalities, in particular no tangle formation, were
seen [20]. In an even more sophisticated approach, Andor-
fer et al. [2] generated a tg mouse model that produces all
six human tau isoforms in the absence of endogenous
mouse (4R) tau, shifting the isoform ratio toward the 3R
variants. Notably, these mice developed tau Wlaments by
the age of 9 months, and pathological tau accumulated in
cell bodies and neuronal dendrites in a spatiotemporal-rele-
vant pattern. Resembling AD pathology, tau aggregation
predominantly occurred in the neocortical neurons and
pyramidal hippocampal cells, whereas brain stem and spi-
nal cord were almost devoid of tau lesions. There was no123
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Subsequently, Van Leuven and co-workers [85] established
a mouse model where the human tau-4R/2N isoform was
expressed in a tau-null background backcrossed into FVB/
N. These mice survive normally and display only a minor
motor phenotype, which occurs late in life in the absence of
tau aggregates [85]. Of note, also in contrast to 4R/2N tg
mouse models with the endogenous mouse tau background
[69, 77] no obvious pathology, in particular no axonopathy
was observed [85]. Instead, in a very similar model of mice
expressing the 4R/2N isoform in a murine tau-k.o. C57/
BL6 background analysis revealed signiWcant increases in
hippocampal volume and neuron numbers with improved
hippocampal memory retention [74]. It was concluded from
this study that 4R-tau serves an important function during
hippocampal development by controlling neuronal precur-
sor proliferation and diVerentiation [74]. Interpreting the
results of these tg models, the ensuing question of whether
endogenous murine tau is inhibitory to tau Wlament forma-
tion, remains to be answered unambiguously. The large
excess of wt human tau in most of these models suYces to
induce mild “pre-tangle” pathology, marked by an abnor-
mal non-Wlamentous accumulation of phosphorylated tau in
cell bodies and dendrites with an associated axonopathy
and variable motor symptoms. However, even with the use
of strong promoters, high-level expression of wt tau is—
with two exceptions [2, 42]—not suYcient to cause the for-
mation of bona Wde NFTs as well as signiWcant neuronal
losses. Remarkably, especially in light of the amyloid cas-
cade hypothesis, this also holds true for mice that coexpress
amyloid precursor protein (APP) harboring the Swedish
and London mutations (APP751SL) and the presenilin-1
M146L mutant (PS1M146L) combined with the human 3R/
0N wt tau transgene under control of a modiWed HMG-CoA
reductase promoter [7]. Only when the human 3R isoform
is expressed under control of the MoPrP promoter, few
Gallyas-positive NFT-like structures are observed in mice
aged 24 months [42]. Moreover, the Andorfer et al. study
[2] recapitulated for the Wrst time tau hyperphosphorylation
with formation of Wbrillary tau aggregates by transgenically
expressing all six human tau isoforms in a murine tau-k.o.
background.
Modeling glial pathology
While the tg mouse models discussed above strongly
focused on studying tau in CNS neurons, the Wlamentous
glial tau pathology characteristic of CBD, PSP, AgD, and
most FTDP-17T cases had been neglected so far. Götz et al.
[30] and Higuchi et al. [34] were the Wrst to report on tg
mice that modeled tau-associated neurodegeneration of
glial cells. When all three isoforms of human 3Rtau were
expressed under the control of the mouse T1 -tubulin
promoter, Wlamentous, Gallyas-positive aggregates remi-
niscent of astrocytic plaques were observed which—
although not speciWc—are considered rather typical lesions
in CBD [13]. These lesions developed in older mice and no
formation of tau aggregates was detected in neurons [34].
Furthermore, recapitulating typical Wndings in PSP, CBD,
and AgD, Gallyas-positive, tau-immunoreactive oligoden-
droglial coiled body-like structures were found which cor-
related with an age-dependent accumulation of Wlamentous
Fig. 1  a Abundant tau stained 
(phosphorylation-dependent 
anti-tau antibody AT8) pre-tan-
gle neurons are observed in sec-
tor CA1 of a transgenic mouse 
strain expressing the longest hu-
man four-repeat tau isoform 
[64]. b Notably this pre-tangle 
pathology is not stained by the 
Gallyas silver technique. c AT8 
stained neuroWbrillary tangles 
(NFT) in the brainstem region of 
a transgenic mouse strain 
expressing the human P301S 
mutation [1]. d In contrast to the 
pre-tangle pathology obtained in 
mouse strains expressing human 
wild-type tau isoforms NFT in 
P301S mice are strongly stained 
with Gallyas. Scale bar a–d: 
100 m123
Acta Neuropathol (2008) 115:39–53 45tau in degenerating oligodendroglial cells [34]. Thus, the
formation of tau-positive glial lesions as they occur in cer-
tain human tauopathies can be modeled in transgenic mice.
As will be discussed in the following section, FTDP-17T-
associated tau mutants were also expressed using alterna-
tive glia-targeting promoters to model human glial tau
pathology [30, 36].
Models with tg expression of human mutant tau 
isoforms (Table 2)
Modeling neuronal pathology
Soon after the identiWcation in 1998 of pathogenic tau
mutations in a subset of FTDP-17 families (reviewed in
[92]), various groups were successful in creating tg mouse
models in which NFT formation was recapitulated in vivo.
Both, neuronal [1, 27, 53, 80, 82] and glial tau Wlamentous
pathologies [30, 36] were demonstrated. Tau gene muta-
tions that underlie the pathogenesis of certain hereditary
tauopathies such as FTDP-17T either occur near splice
sites, changing ratios within the expressed tau isoform rep-
ertoire, or occur as missense mutations, both of which
likely aVect the binding aYnity of tau toward microtubules.
In the Wrst reported mouse model which successfully dem-
onstrated the formation of NFTs, the human P301L muta-
tion, which results in pronounced adverse eVects on
microtubule-assembly promoting activity [4], was
expressed under the control of the MoPrP promoter [53]
leading in homozygous mice to mutant human tau expres-
sion at a twofold level in comparison to endogenous murine
levels. In homozygous mice, motor and behavioral deWcits
related to NFT formation started to develop at 4.5 months
with NFTs and Pick body-like neuronal lesions occurring in
amygdala, mid-brain, brain stem and spinal cord, and with
pre-tangle tau pathology in the neocortex, hippocampus,
and basal ganglia. In addition to a signiWcant reduction of
spinal cord motor neurons that almost reached 50%, a
peripheral neuropathy accompanied by neurogenic muscle
atrophy was observed. Biochemically, the presence of Gall-
yas-positive NFTs containing hyperphosphorylated tau was
demonstrated. One of the signiWcant advances achieved
through this model was that, for the Wrst time, a link
between neuroWbrillary pathology and neuronal loss was
established. Remarkably, a relatively low transgene expres-
sion level was suYcient to trigger Wbrillary tau aggregates.
In contrast, previous mouse models with higher expression
levels of the human wt tau transgene failed to cause NFT
formation, which likely reXects the pathogenicity of P301L
as the most common tau gene mutation associated with
FTDP-17T (reviewed in [92]).
Expressing the same P301L transgene, however under
the control of the murine thy-1.2 promoter, Götz et al. [27]
similarly observed hyperphosphorylation of accumulated
tau which appeared redistributed from its normal axonal
localization to somatodendritic compartments. In addition,
as demonstrated by electron microscopy, short Wlament for-
mation occurred in the cortex, brain stem and spinal cord
[27]. Likewise, using a very similar model controlled by the
murine thy-1 promoter, wt human 4R/2N tau was expressed
in one mouse strain comparatively to the P301L mutation
[85]. Whereas in the wt tau mice motor symptoms were
evident already at 6–8 weeks, no tau aggregates formed and
the animals had a normal life span. In contrast, in the
P301L transgene-expressing mice, progressive Wbrillary tau
aggregation started to develop at around 6 months of age
and, despite only minor motor problems, animals died prior
to the age of 13 months [85]. Tangle-like tau pathology was
also observed in mice that expressed the P301L mutation in
combination with a tet-oV regulated CaMK-II promoter
system [70, 72]. As expected, high-level P301L expressing
mice developed pre-tangles as early as at 2.5 months of
age, with rapid progression of tau pathology culminating
both in NFT formation by around 4 months of age and
marked cognitive impairment. NFTs were Wrst observed in
the neocortex and, with increasing age, progressed to the
hippocampus and the limbic system [70, 72]. Remarkably,
when transgenic P301L expression was suppressed by
administration of doxycycline, memory function was sig-
niWcantly improved, but NFTs continued to accumulate,
and a region-speciWc dissociation between neuronal loss
and the occurrence of NFTs was veriWed [76]. This may
also be related to a postulated dissociation between the
mechanisms causing memory impairment and those leading
to tau Wbrillation. It seems that in this model NFTs per se
are not the primary cause of the observed cognitive deWcits
[72] which may rather be reXections of a reversible neuro-
nal dysfunction.
Interestingly, proteomic analyses of P301L tg mice
revealed a mitochondrial dysfunction related to modiWca-
tion in the expression patterns of mitochondrial respiratory
chain complex components, antioxidant enzymes impli-
cated in detoxiWcation of reactive oxygen species (ROS)
and of synapse-associated proteins [18]. In the context of
tauopathies, mitochondrial dysfunction has also indepen-
dently been corroborated in vivo by several groups. For
instance, chronic rotenone-mediated complex I inhibition is
suYcient to trigger a cerebral tauopathy with tau accumula-
tions occurring in neurons, astrocytes, and oligodendro-
cytes [38].
In mice expressing the human P301S tau mutant associ-
ated with early onset FTDP-17T, two groups demonstrated
neurodegeneration leading to nerve cell loss. In these mod-
els starting at 5–6 months, Wlamentous hyperphosphory-
lated tau pathology develops in brain stem and spinal cord
with a signiWcant reduction of spinal cord motor neurons in123
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48 Acta Neuropathol (2008) 115:39–53homozygous mice in conjunction with severe paraparesis
[1, 5, 97] (Fig. 1c, d). Remarkably, Bellucci et al. [5] also
reported on microglia activation—recently implicated in
the clearance of A deposits (for review see [96])—adja-
cent to tau-positive neurons.
In an alternative model of FTDP-17T, the human
V337M mutation that is weaker in comparison to the
P301L mutation with regard to aVecting microtubule-
assembly was expressed under the control of the PDGF-
promoter. This resulted in the formation of tau-containing
NFTs in the hippocampus and in various behavioral abnor-
malities [81]. Similarly, when the FTDP-17T—associated
R406W mutation was expressed using the CaMK-II pro-
moter, congophilic hyperphosphorylated tau inclusions
formed in the forebrain starting at 18 months of age, with
aged mice exhibiting an impaired associative memory but
no signiWcant sensorimotor deWcits. Sarcosyl-insoluble tau
was recovered from old tg mice only [82]. Expression of
the same mutant, but under control of the Syrian hamster
prion protein promoter, led to the development of Wlamen-
tous tau aggregations in the hippocampus and amygdala
with subsequent spreading of tau pathology to neocortical
and subcortical regions. Accumulated, sarcosyl-insoluble
tau was found to be phosphorylated, ubiquitinated, and
stainable with the Gallyas silver impregnation method [40].
Again, in analogy to the P301S mouse model reported by
Bellucci et al. [5], a pronounced activation of microglia was
prominent. Behavioral tests of the R406W tg mice revealed
motor symptoms as well as progressive loss of acquired
memory at the age of 10–12 months [40]. In a third tg
human tau R406W mouse strain, with expression driven by
the MoPrP promoter, Zhang et al. [98] similarly observed
Wlamentous tau lesions with advancing age, which occurred
in neuronal perikarya of the cerebral cortex, hippocampus,
cerebellum, and spinal cord. Interestingly, when compared
to otherwise identical tg mice expressing human wt tau,
reduced tau levels were found in CNS axons and linked to
retarded axonal transport, presumably resulting from an
accumulation of insoluble R406W but not human wt tau
protein [98]. In yet another model, where G272V and
P301S mutations were coexpressed in a thy-1.2-regulated
manner, hyperphosphorylation and Gallyas-positive NFT-
like pathology were observed. These mice developed defec-
tive hippocampal synaptic transmission as well as behav-
ioral and cognitive abnormalities such as increased anxiety,
learning deWcits, and impaired spatial memory [73].
Finally, Lim et al. [54] reported on a tg mouse model
expressing human triple mutant tau under control of the
murine thy-1 promoter. All of these mutants (G272V,
P301L, and R406W) have been found in FTDP-17T kin-
dreds [39]. Transgenic expression of this triple mutant at
relatively low levels led to Wbrillar, hyperphosphorylated
tau pathology in neurons, in particular of cortical and
hippocampal regions. Transgene expression was low in the
spinal cord, and no obvious motor deWcits were observed
up to 12 months [54].
In summary, in mouse lines engineered to express
FTDP-17T-associated missense mutations, abundant Wla-
ments containing hyperphosphorylated tau protein devel-
oped, which was associated with neuronal cell loss. The
fact that phosphorylation was observed in soluble tau points
to the fact that hyperphosphorylation is likely to occur prior
to Wlament assembly. Indeed, as demonstrated [63], an
increase in tau phosphorylation in the soluble tau fraction
may result in increased Wlament formation, indicating that
phosphorylation of tau plays a contributory, if not causal
role in the process of tau self-aggregation [63]. However,
one crucial question that has not been answered yet in vivo
is whether tau phosphorylation represents a primary event
or occurs secondarily to the tau protein undergoing subtle
conformational (pathological) changes.
Modeling glial pathology
Finally, two tg models where FTDP-17T mutations were
expressed to model glial tau pathology, shall be brieXy
mentioned here. In the Wrst approach, Götz et al. [30]
expressed the human G272V mutation with a MoPrP pro-
moter-autoregulatory tetracycline-dependent transactivator
system and found transgene expression in neurons as well
as oligodendrocytes. Although formation of Wlamentous tau
associated with phosphorylation of the protein was
observed, these mice did not develop any obvious neuro-
logical deWcits [30]. In yet another P301L tg mouse strain
with transgene expression regulated by an oligodendrocyte-
speciWc promoter [2,3-cyclic nucleotide 3-phosphodies-
terase (CNP)], Higuchi et al. [36] demonstrated the mutant
tau in CNS oligodendrocytes to become insoluble and Wla-
mentous at 15 months of age. In these mice, disruption of
myelin and axonal degeneration occurred, and subsequent
motor deWcits developed. Finally, coiled body-like NFT
formation in oligodendrocytes was also revealed in tg
P301L mice (MoPrP promoter) described earlier [53, 55].
Double and triple transgenic mice as models for AD 
pathogenesis (Table 2)
Alzheimer’s disease is neuropathologically characterized by
two signature lesions, extracellular plaque-like deposition of
A as well as intracellular formation of NFTs containing
hyperphosphorylated tau. Despite several decades of
research eVorts, it is still not known whether or not both
pathologies are causally related to each other. According to
the amyloid cascade hypothesis [32], and possibly in the
reality of AD, they are in that A is likely to function
upstream to trigger tau pathology. Along these lines, A123
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activity, thereby enhancing tau accumulation [89]. More-
over, APP mutations are causally linked to early onset forms
of AD, but no tau mutations have ever been linked to the
disease. However, at least outside the context of AD, the
general validity of the hypothesis can be questioned by a
number of observations. First, in PSP, CBD, AgD, and
FTDP-17T, neurodegeneration occurs in the absence of A
pathology. Second, it is interesting to note that tg mutant
APP mice, despite showing extensive parenchymal and
vascular amyloid pathology, do not develop robust tauopathy-
related changes (see review by van Leuven [91]). Furthermore,
it was recently reported that intraneuronal A immunoreac-
tivity may not be predictive of neuroWbrillary tau pathology
[94]. On the other hand, double tg mice, coexpressing
mutant APP and the P301L tau mutation develop not only
A as well as tau pathology, but also display amyotrophy
and severe motor problems [52]. In addition, triple tg mice
(3xTg-AD) overexpressing mutant APP (harboring the
Swedish mutation), the M146V presenilin-1 mutant, and the
P301L mutant tau, exhibit a combined, progressive tau and
amyloid pathology [66]. Synaptic dysfunction with deWcits
in long-term potentiation manifested prior to the occurrence
of plaques and tangles [66]. Interestingly, in this model
amyloid deposition precedes NFT formation, consistent
with the amyloid cascade hypothesis [65]. Moreover, when
proteasome function is blocked in 3xTg-AD mice at a pre-
pathological stage, a marked increase in tau as well as A
accumulation ensues [89]. Furthermore, by intracerebrally
injecting A42 Wbrils into P301L mice an increase in NFTs
was triggered in the amygdala from where neuronal projec-
tions run to the injection sites, which is clearly indicative of
a pathogenic link between A and tau [28].
In another recent approach it was tested whether lower-
ing the expression of endogenous tau could block A-
induced cognitive impairments. To this end, human APP
transgenic mice [60] were crossed with tau knockout ani-
mals. Remarkably, ablation of endogenous murine tau pre-
vents the A-dependent behavioral deWcits that typically
develop in human tg APP mice, without having any mea-
surable eVects on amyloid plaque load [71]. Another impor-
tant aspect of that same work [71] is that tau may have a
role in regulating nerve cell activity and that lowering lev-
els of tau expression might represent a strategy to inhibit
hyperexcitability-induced damage of CNS neurons; the
underlying molecular correlates of this excitotoxic tau
eVect remain to be clariWed.
Therapeutic approaches
So far, available therapeutic approaches have only met with
limited success, with only a few approved modalities that—
only transiently—slow cognitive decline [58]. Perhaps,
unless the primary cause(s) triggering the neuronal cell
death cascade in tauopathies are targeted, there are only
modest chances to succeed in developing highly eYcient
therapeutic strategies capable of preventing or at least halt-
ing the vicious circle of neurodegeneration in these disor-
ders.
According to the amyloid cascade hypothesis, reduction
of the culprit A, supposed to act upstream of tau, appears
to be an obvious strategy. However, recent reports (e.g.
[71]) indicate that reducing tau may be an equally war-
ranted, eVective, and possibly complementing approach.
A number of additional strategies are conceivable, one
of them targeting abnormal tau phosphorylation. The lon-
gest adult tau variants contain almost 80 potential serine
and threonine phosphorylation sites, although only about 30
of them seem to be functionally relevant under physiologi-
cal conditions [12]. The phosphorylation status of tau can
be modulated by the prolyl-isomerase Pin1 [56] which cata-
lyzes the conversion between two distinct phospho(Ser/
Thr)-Pro motif conformations, thereby perhaps also indi-
rectly promoting tau dephosphorylation. Interestingly, Pin1
knockout mice exhibit progressive, age-dependent motor
and behavioral deWcits, accompanied by tau hyperphosph-
orylation, tau Wlament formation, and neuronal degenera-
tion [56]. Apart from Pin1, in particular three kinases,
GSK-3 [57], CDK5 [63], and ERK2 [47] have been associ-
ated with modulating tau phosphorylation in vivo. Of note,
tg mice overexpressing GSK-3 display tau hyperphosph-
orylation, disrupted microtubules, and apoptotic neurons
[57]. Interestingly, conditional expression of dominant-
negative GSK-3 (unexpectedly, the constitutive GSK-3
knockout is embryonically lethal due to massive apoptosis
in the liver [37]), leads to increased neuronal apoptosis and
motor symptoms, both of which are suppressed when trans-
gene expression is switched oV [25]. In another experimen-
tal approach, the administration of an orally bioavailable,
blood-brain barrier-penetrating small molecule inhibitor of
ERK2 to tg P301L mice was eVective not only at signiW-
cantly reducing hyperphosphorylated tau but also in pre-
venting the typical motor deWcits in these animals.
Remarkably, however, there was no concomitant reduction
of NFTs, suggesting that tau cytotoxicity is not so much
exerted by NFTs but may rather be caused by smaller tau
aggregates. The prevention of hyperphosphorylation
through inhibition of one of the tau-phosphorylating kin-
ases may also point to a crucial pathogenic role of dysregu-
lated tau phosphorylation in tauopathies [47].
However, CDK5, ERK2, and GSK-3 also function to reg-
ulate various important physiological pathways, necessitating
the design of kinase inhibitors that eVectively suppress tau
hyperphosphorylation while showing only minimal toxic-
ity through oV-target eVects. If successful, such kinase123
50 Acta Neuropathol (2008) 115:39–53inhibitors (recently reviewed in [59]) might yield a valuable
adjunct to currently available treatment options.
In addition, administration of lithium-chloride, a drug
traditionally used in the treatment of bipolar disorders, has
recently been shown not only to inhibit GSK-3 activity but
also to result in decreased tau pathology [62], which
strongly correlated with markedly reduced axonal degener-
ation in P301L tg mice [64]. Other alternative (although
currently more theoretic) approaches could be aimed at pre-
venting the proteolytic cleavage-mediated generation of
small, nucleation-promoting tau fragments through inhibi-
tion of speciWc proteases such as calpain or caspases [15,
35]. Stabilizing microtubules might represent another
potential therapeutic avenue (for review see [87]). Agents
with respective activity, in particular taxols such as paclit-
axel are commonly used in cancer treatment (recently
reviewed in [45]). As they act on dividing cells, adverse
eVects are hard to be avoided. Nevertheless, treatment of tg
mice expressing the 3R/0N isoform of human wt tau with
paclitaxel resulted not only in the restoration of fast axonal
transport but also led to the improvement of motor deWcits
[99]. Finally, as A oligomers were recently demonstrated
to enhance tau accumulation through impaired proteasome
activity, the proteasome appears to be another attractive tar-
get for therapeutic intervention [89].
Open questions
Admittedly, despite decades of intense research, many of
the central questions underlying the pathogenic mecha-
nisms in tauopathies still remain unanswered. In particular,
the nature of the triggering event(s) initiating tau aggrega-
tion in vivo remains enigmatic. One of the questions that
arises in that context is whether tau phosphorylation is a
general prerequisite for Wlament formation and if so, how
both processes are linked. To what extent are the nucle-
ation-promoting eVects mediated by smaller, proteolyti-
cally derived tau fragments important events in Wlamentous
aggregation? If the amyloid cascade hypothesis is correct,
what are the mechanisms of A triggering tau Wlament
assembly? Which species of tau are the toxic ones? Do Wla-
mentous tau aggregates even act in a protective way by pro-
moting the sequestration of the toxic species? Finally, what
is the role of inXammation related to the development of tau
pathology? What is the basis for the AD-stage-speciWc spa-
tio-temporal distribution of tau lesions?
Conclusions
Despite the fact that the available animal models cannot
suYciently mirror the complex pathogenesis of human tau-
opathies, they will continue to provide important new
insights into the molecular pathways at play in these disor-
ders. In particular, genetically engineered mouse models
will continue to lead the way in tauopathy research. Rather
than completely reXecting the entire pathogenic process
with all its diVerent aspects, they can be used to adequately
recapitulate crucial aspects of these disorders. One of their
particular strengths is that, even under the highly artiWcial
conditions of transgene overexpression, our comprehen-
sion/understanding of tauopathies can be further expanded
by studies of protein interactions as well as of induced pro-
tein modiWcations and their consequences. Last but not
least, using worms and Xies may pay oV as well, e.g., in
high-throughput drug-screens which may lead to the identi-
Wcation of agents that lend themselves for the designing of
novel therapeutic strategies for these devastating diseases.
Acknowledgments FC and MC are supported by the Swiss National
Science Foundation (3100-068328).
References
1. Allen B, Ingram E, Takao M, Smith MJ, Jakes R, Virdee K, Yosh-
ida H, Holzer M, Craxton M, Emson PC, Atzori C, Migheli A,
Crowther RA, Ghetti B, Spillantini MG, Goedert M (2002) Abun-
dant tau Wlaments and nonapoptotic neurodegeneration in trans-
genic mice expressing human P301S tau protein. J Neurosci
22:9340–9351
2. Andorfer C, Kress Y, Espinoza M, de Silva R, Tucker KL, Barde
YA, DuV K, Davies P (2003) Hyperphosphorylation and aggrega-
tion of tau in mice expressing normal human tau isoforms. J Neu-
rochem 86:582–590
3. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, Wiche
G, Seitelberger F, Grundke-Iqbal I, Iqbal K, Wisniewski H (1989)
Accumulation of abnormally phosphorylated tau precedes the for-
mation of neuroWbrillary tangles in Alzheimer’s disease. Brain Res
477:90–99
4. Barghorn S, Zheng-Fischhöfer Q, Ackmann M, Biernat J, von Ber-
gen M, Mandelkow EM, Mandelkow E (2000) Structure, microtu-
bule interactions, and paired helical Wlament aggregation by tau
mutants of frontotemporal dementias. Biochemistry 39:11714–
11721
5. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M,
Spillantini MG (2004) Induction of inXammatory mediators and
microglial activation in mice transgenic for mutant human P301S
tau protein. Am J Pathol 165:1643–1652
6. Bonini NM, Fortini ME (2003) Human neurodegenerative disease
modeling using Drosophila. Annu Rev Neurosci 26:627–656
7. Boutajangout A, Authelet M, Blanchard V, Touchet N, Tremp G,
Pradier L, Brion JP (2004) Characterisation of cytoskeletal abnor-
malities in mice transgenic for wild-type human tau and familial
Alzheimer’s disease mutants of APP and presenilin-1. Neurobiol
Dis 15:47–60
8. Braak E, Braak H, Mandelkow EM (1994) A sequence of cytoskel-
eton changes related to the formation of neuroWbrillary tangles and
neuropil threads. Acta Neuropathol (Berl) 87:554–567
9. Braak H, Braak E (1991) Neuropathological stageing of Alzhei-
mer-related changes. Acta Neuropathol (Berl) 82:239–259
10. Brandt R, Gergou A, Wacker I, Fath T, Hutter H (2007) A Caenor-
habditis elegans model of tau hyperphosphorylation: induction of123
Acta Neuropathol (2008) 115:39–53 51developmental defects by transgenic overexpression of Alzhei-
mer’s disease-like modiWed tau. Neurobiol Aging. June 21 [Epub
ahead of print]
11. Brion JP, Tremp G, Octave JN (1999) Transgenic expression of
the shortest human tau aVects its compartmentalization and its
phosphorylation as in the pretangle stage of Alzheimer’s disease.
Am J Pathol 154:255–270
12. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PR
(2000) Tau protein isoforms, phosphorylation and role in neurode-
generative disorders. Brain Res Brain Res Rev 33:95–130
13. Cairns NJ, Bigio EH, Mackenzie IR, Neumann M, Lee VM, Hat-
anpaa KJ, White CL, Schneider JA, Grinberg LT, Halliday G,
Duyckaerts C, Lowe JS, Holm IE, Tolnay M, Okamoto K, Yokoo
H, Murayama S, Woulfe J, Munoz DG, Dickson DW, Ince PG,
Trojanowski JQ, Mann DM (2007) Neuropathologic diagnostic
and nosologic criteria for frontotemporal lobar degeneration: con-
sensus of the Consortium for Frontotemporal Lobar Degeneration.
Acta Neuropathol (Berl) 114:5–22
14. Coleman PD, Yao PJ (2003) Synaptic slaughter in Alzheimer’s
disease. Neurobiol Aging 24:1023–1027
15. Cotman CW, Poon WW, Rissman RA, Blurton-Jones M (2005)
The role of caspase cleavage of tau in Alzheimer disease neuropa-
thology. J Neuropathol Exp Neurol 64:104–112
16. Cruz JC, Tsai LH (2004a) A Jekyll and Hyde kinase: roles for
Cdk5 in brain development and disease. Curr Opin Neurobiol
14:390–394
17. Cruz JC, Tsai LH (2004b) Cdk5 deregulation in the pathogenesis
of Alzheimer’s disease. Trends Mol Med 10:452–458
18. David DC, Hauptmann S, Scherping I, Schuessel K, Keil U, Rizzu
P, Ravid R, Dröse S, Brandt U, Müller WE, Eckert A, Götz J (2005)
Proteomic and functional analyses reveal a mitochondrial dysfunc-
tion in P301L tau transgenic mice. J Biol Chem 280:23802–23814
19. Dawson HN, Ferreira A, Eyster MV, Ghoshal N, Binder LI, Vitek
MP (2001) Inhibition of neuronal maturation in primary hippo-
campal neurons from tau deWcient mice. J Cell Sci 114:1179–1187
20. DuV K, Knight H, Refolo LM, Sanders S, Yu X, Picciano M, Mal-
ester B, Hutton M, Adamson J, Goedert M, Burki K, Davies P
(2000) Characterization of pathology in transgenic mice over-
expressing human genomic and cDNA tau transgenes. Neurobiol
Dis 7:87–98
21. Ebneth A, Godemann R, Stamer K, Illenberger S, Trinczek B,
Mandelkow E (1998) Overexpression of tau protein inhibits kine-
sin-dependent traYcking of vesicles, mitochondria, and endoplas-
mic reticulum: implications for Alzheimer’s disease. J Cell Biol
143:777–794
22. Fortini ME, Bonini NM (2000) Modeling human neurodegenera-
tive diseases in Drosophila: on a wing and a prayer. Trends Genet
16:161–167
23. Goedert M (1996) Tau protein and the neuroWbrillary pathology of
Alzheimer’s disease. Ann NY Acad Sci 777:121–131
24. Goedert M, Spillantini MG (2006) A century of Alzheimer’s dis-
ease. Science 314:777–781
25. Gomez-Sintes R, Hernandez F, Bortolozzi A, Artigas F, Avila J,
Zaratin P, Gotteland JP, Lucas JJ (2007) Neuronal apoptosis and
reversible motor deWcit in dominant-negative GSK-3 conditional
transgenic mice. EMBO J 26:2743–2754
26. Goode BL, Feinstein SC (1994) IdentiWcation of a novel microtu-
bule binding and assembly domain in the developmentally regu-
lated inter-repeat region of tau. J Cell Biol 124:769–782
27. Götz J, Chen F, Barmettler R, Nitsch RM (2001a) Tau Wlament
formation in transgenic mice expressing P301L tau. J Biol Chem
276:529–534
28. Götz J, Chen F, van Dorpe J, Nitsch RM (2001b) Formation of
neuroWbrillary tangles in P301l tau transgenic mice induced by
Abeta 42 Wbrils. Science 293:1491–1495
29. Götz J, Probst A, Spillantini MG, Schafer T, Jakes R, Burki K,
Goedert M (1995) Somatodendritic localization and hyperphosph-
orylation of tau protein in transgenic mice expressing the longest
human brain tau isoform. Embo J 14:1304–1313
30. Götz J, Tolnay M, Barmettler R, Chen F, Probst A, Nitsch RM
(2001c) Oligodendroglial tau Wlament formation in transgenic
mice expressing G272V tau. Eur J Neurosci 13:2131–2140
31. Harada A, Oguchi K, Okabe S, Kuno J, Terada S, Ohshima T,
Sato-Yoshitake R, Takei Y, Noda T, Hirokawa N (1994) Altered
microtubule organization in small-calibre axons of mice lacking
tau protein. Nature 369:488–491
32. Hardy J (2006) Has the amyloid cascade hypothesis for Alzhei-
mer’s disease been proved? Curr Alzheimer Res 3:71–73
33. Heidary G, Fortini ME (2001) IdentiWcation and characterization
of the Drosophila tau homolog. Mech Dev 108:171–178
34. Higuchi M, Ishihara T, Zhang B, Hong M, Andreadis A, Troja-
nowski J, Lee VM (2002) Transgenic mouse model of tauopathies
with glial pathology and nervous system degeneration. Neuron
35:433–446
35. Higuchi M, Tomioka M, Takano J, Shirotani K, Iwata N, Masum-
oto H, Maki M, Itohara S, Saido TC (2005a) Distinct mechanistic
roles of calpain and caspase activation in neurodegeneration as re-
vealed in mice overexpressing their speciWc inhibitors. J Biol
Chem 280:15229–15237
36. Higuchi M, Zhang B, Forman MS, Yoshiyama Y, Trojanowski JQ,
Lee VM (2005b) Axonal degeneration induced by targeted expres-
sion of mutant human tau in oligodendrocytes of transgenic mice
that model glial tauopathies. J Neurosci 25:9434–9443
37. HoeXich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR
(2000) Requirement for glycogen synthase kinase-3beta in cell
survival and NF-kappaB activation. Nature 406:86–90
38. Höglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duycka-
erts C, Féger J, Champy P, Prigent A, Medja F, Lombes A, Oertel
WH, Ruberg M, Hirsch EC (2005) The mitochondrial complex I
inhibitor rotenone triggers a cerebral tauopathy. J Neurochem
95:930–939
39. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, Houlden H,
Pickering-Brown S, Chakraverty S, Isaacs A, Grover A, Hackett J,
Adamson J, Lincoln S, Dickson D, Davies P, Petersen RC, Stevens
M, de GraaV E, Wauters E, van Baren J, Hillebrand M, Joosse M,
Kwon JM, Nowotny P, Che LK, Norton J, Morris JC, Reed LA,
Trojanowski J, Basun H, Lannfelt L, Neystat M, Fahn S, Dark F,
Tannenberg T, Dodd PR, Hayward N, Kwok JB, SchoWeld PR,
Andreadis A, Snowden J, Craufurd D, Neary D, Owen F, Oostra
BA, Hardy J, Goate A, van Swieten J, Mann D, Lynch T, Heutink
P (1998) Association of missense and 5-splice-site mutations in
tau with the inherited dementia FTDP-17. Nature 393:702–705
40. Ikeda M, Shoji M, Kawarai T, Kawarabayashi T, Matsubara E,
Murakami T, Sasaki A, Tomidokoro Y, Ikarashi Y, Kuribara H,
Ishiguro K, Hasegawa M, Yen SH, Chishti MA, Harigaya Y, Abe
K, Okamoto K, St George-Hyslop P, Westaway D (2005) Accu-
mulation of Wlamentous tau in the cerebral cortex of human tau
R406W transgenic mice. Am J Pathol 166:521–531
41. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, Trojanow-
ski JQ, Lee VM (1999) Age-dependent emergence and progres-
sion of a tauopathy in transgenic mice overexpressing the shortest
human tau isoform. Neuron 24:751–762
42. Ishihara T, Zhang B, Higuchi M, Yoshiyama Y, Trojanowski JQ,
Lee VM (2001) Age-dependent induction of congophilic neuroW-
brillary tau inclusions in tau transgenic mice. Am J Pathol
158:555–562
43. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA,
Massachi S, Geschwind DH (2002) Human wild-type tau interacts
with wingless pathway components and produces neuroWbrillary
pathology in Drosophila. Neuron 34:509–519123
52 Acta Neuropathol (2008) 115:39–5344. Kaytor MD, Orr HT (2002) The GSK3 beta signaling cascade and
neurodegenerative disease. Curr Opin Neurobiol 12:275–278
45. Kingston DG, Newman DJ (2007) Taxoids: cancer-Wghting com-
pounds from nature. Curr Opin Drug Discov Devel 10:130–144
46. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ,
Schellenberg GD (2003) Neurodegeneration and defective neuro-
transmission in a Caenorhabditis elegans model of tauopathy.
Proc Natl Acad Sci USA 100:9980–9985
47. Le Corre S, Klafki HW, Plesnila N, Hübinger G, Obermeier A, Sa-
hagún H, Monse B, Seneci P, Lewis J, Eriksen J, Zehr C, Yue M,
McGowan E, Dickson DW, Hutton M, Roder HM (2006) An
inhibitor of tau hyperphosphorylation prevents severe motor
impairments in tau transgenic mice. Proc Natl Acad Sci USA
103:9673–9678
48. Lee MS, Kwon YT, Li M, Peng J, Friedlander RM, Tsai LH (2000)
Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature
405:360–364
49. Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative
tauopathies. Annu Rev Neurosci 24:1121–1159
50. Lee VM, Kenyon TK, Trojanowski JQ (2005) Transgenic animal
models of tauopathies. Biochim Biophys Acta 1739:251–259
51. Lee VM, Trojanowski JQ (2001) Transgenic mouse models of tau-
opathies: prospects for animal models of Pick’s disease. Neurol-
ogy 56:S26–S30
52. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G,
Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J, Hut-
ton M, McGowan E (2001) Enhanced neuroWbrillary degeneration
in transgenic mice expressing mutant tau and APP. Science
293:1487–1491
53. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van
Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu
X, DuV K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW,
Davies P, Hutton M (2000) NeuroWbrillary tangles, amyotrophy
and progressive motor disturbance in mice expressing mutant
(P301L) tau protein. Nat Genet 25:402–405
54. Lim F, Hernández F, Lucas JJ, Gómez-Ramos P, Móran MA, Av-
ila J (2001) FTDP-17 mutations in tau transgenic mice provoke
lysosomal abnormalities and Tau Wlaments in forebrain. Mol Cell
Neurosci 18:702–714
55. Lin WL, Lewis J, Yen SH, Hutton M, Dickson DW (2003) Fila-
mentous tau in oligodendrocytes and astrocytes of transgenic mice
expressing the human tau isoform with the P301L mutation. Am J
Pathol 162:213–218
56. Liou YC, Sun A, Ryo A, Zhou XZ, Yu ZX, Huang HK, Uchida T,
Bronson R, Bing G, Li X, Hunter T, Lu KP (2003) Role of the prol-
yl isomerase Pin1 in protecting against age-dependent neurode-
generation. Nature 424:556–561
57. Lucas JJ, Hernández F, Gómez-Ramos P, Móran MA, Hen R, Av-
ila J (2001) Decreased nuclear beta-catenin, tau hyperphosphory-
lation and neurodegeneration in GSK-3beta conditional transgenic
mice. Embo J 20:27–39
58. Marx J (2007) Alzheimer’s disease. A new take on tau. Science
316:1416–1417
59. Mazanetz MP, Fischer PM (2007) Untangling tau hyperphosph-
orylation in drug design for neurodegenerative diseases. Nat Rev
Drug Discov 6:464–479
60. Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tat-
suno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L
(2000) High-level neuronal expression of abeta 1-42 in wild-type
human amyloid protein precursor transgenic mice: synaptotoxicity
without plaque formation. J Neurosci 20:4050–4058
61. Miyasaka T, Ding Z, Gengyo-Ando K, Oue M, Yamaguchi H, Mi-
tani S, Ihara Y (2005) Progressive neurodegeneration in C. elegans
model of tauopathy. Neurobiol Dis 20:372–383
62. Nakashima H, Ishihara T, Suguimoto P, Yokota O, Oshima E,
Kugo A, Terada S, Hamamura T, Trojanowski JQ, Lee VM,
Kuroda S (2005) Chronic lithium treatment decreases tau lesions
by promoting ubiquitination in a mouse model of tauopathies.
Acta Neuropathol (Berl) 110:547–556
63. Noble W, Olm V, Takata K, Casey E, Mary O, Meyerson J, Gay-
nor K, LaFrancois J, Wang L, Kondo T, Davies P, Burns M, Veer-
anna, Nixon R, Dickson D, Matsuoka Y, Ahlijanian M, Lau LF,
DuV K (2003) Cdk5 is a key factor in tau aggregation and tangle
formation in vivo. Neuron 38:555–565
64. Noble W, Planel E, Zehr C, Olm V, Meyerson J, Suleman F, Gay-
nor K, Wang L, LaFrancois J, Feinstein B, Burns M, Krishnamur-
thy P, Wen Y, Bhat R, Lewis J, Dickson D, DuV K (2005)
Inhibition of glycogen synthase kinase-3 by lithium correlates
with reduced tauopathy and degeneration in vivo. Proc Natl Acad
Sci USA 102:6990–6995
65. Oddo S, Caccamo A, Kitazawa M, Tseng BP, LaFerla FM (2003a)
Amyloid deposition precedes tangle formation in a triple trans-
genic model of Alzheimer’s disease. Neurobiol Aging 24:1063–
1070
66. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed
R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003b) Tri-
ple-transgenic model of Alzheimer’s disease with plaques and tan-
gles: intracellular Abeta and synaptic dysfunction. Neuron
39:409–421
67. Park SY, Ferreira A (2005) The generation of a 17 kDa neurotoxic
fragment: an alternative mechanism by which tau mediates beta-
amyloid-induced neurodegeneration. J Neurosci 25:5365–5375
68. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, Ander-
son L, Andreadis A, Wiederholt WC, Raskind M, Schellenberg
GD (1998) Tau is a candidate gene for chromosome 17 frontotem-
poral dementia. Ann Neurol 43:815–825
69. Probst A, Götz J, Wiederhold KH, Tolnay M, Mistl C, Jaton AL,
Hong M, Ishihara T, Lee VM, Trojanowski JQ, Jakes R, Crowther
RA, Spillantini MG, Burki K, Goedert M (2000) Axonopathy and
amyotrophy in mice transgenic for human four-repeat tau protein.
Acta Neuropathol (Berl) 99:469–481
70. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, San-
taCruz K, Guimaraes A, Yue M, Lewis J, Carlson G, Hutton M,
Ashe KH (2005) Age-dependent neuroWbrillary tangle formation,
neuron loss, and memory impairment in a mouse model of human
tauopathy (P301L). J Neurosci 25:10637–10647
71. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T,
Gerstein H, Yu GQ, Mucke L (2007) Reducing endogenous tau
ameliorates amyloid beta-induced deWcits in an Alzheimer’s dis-
ease mouse model. Science 316:750–754
72. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson
M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C,
Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B,
Hutton M, Ashe KH (2005) Tau suppression in a neurodegenera-
tive mouse model improves memory function. Science 309:476–
481
73. Schindowski K, Bretteville A, Leroy K, Begard S, Brion JP, Ham-
dane M, Buee L (2006) Alzheimer’s disease-like tau neuropathol-
ogy leads to memory deWcits and loss of functional synapses in a
novel mutated tau transgenic mouse without any motor deWcits.
Am J Pathol 169:599–616
74. Sennvik K, Boekhoorn K, Lasrado R, Terwel D, Verhaeghe S,
Korr H, Schmitz C, Tomiyama T, Mori H, Krugers H, Joels M, Ra-
makers GJ, Lucassen PJ, Van Leuven F (2007) Tau-4R suppresses
proliferation and promotes neuronal diVerentiation in the hippo-
campus of tau knockin/knockout mice. Faseb J 21:2149–2161
75. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A,
Ghetti B (1998) Mutation in the tau gene in familial multiple sys-
tem tauopathy with presenile dementia. Proc Natl Acad Sci USA
95:7737–7741
76. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, Ashe
KH, Hyman BT (2006) Region-speciWc dissociation of neuronal123
Acta Neuropathol (2008) 115:39–53 53loss and neuroWbrillary pathology in a mouse model of tauopathy.
Am J Pathol 168:1598–1607
77. Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Van-
dezande K, Laenen I, Geerts H, Mercken M, Sciot R, Van Lommel
A, Loos R, Van Leuven F (1999) Prominent axonopathy in the
brain and spinal cord of transgenic mice overexpressing four-re-
peat human tau protein. Am J Pathol 155:2153–2165
78. Spittaels K, Van den Haute C, Van Dorpe J, Geerts H, Mercken M,
Bruynseels K, Lasrado R, Vandezande K, Laenen I, Boon T, Van
Lint J, Vandenheede J, Moechars D, Loos R, Van Leuven F (2000)
Glycogen synthase kinase-3beta phosphorylates protein tau and
rescues the axonopathy in the central nervous system of human
four-repeat tau transgenic mice. J Biol Chem 275:41340–41349
79. Stamer K, Vogel R, Thies E, Mandelkow E, Mandelkow EM
(2002) Tau blocks traYc of organelles, neuroWlaments, and APP
vesicles in neurons and enhances oxidative stress. J Cell Biol
156:1051–1063
80. Tanemura K, Akagi T, Murayama M, Kikuchi N, Murayama O,
Hashikawa T, Yoshiike Y, Park JM, Matsuda K, Nakao S, Sun X,
Sato S, Yamaguchi H, Takashima A (2001) Formation of Wlamen-
tous tau aggregations in transgenic mice expressing V337M hu-
man tau. Neurobiol Dis 8:1036–1045
81. Tanemura K, Murayama M, Akagi T, Hashikawa T, Tominaga T,
Ichikawa M, Yamaguchi H, Takashima A (2002) Neurodegenera-
tion with tau accumulation in a transgenic mouse expressing
V337M human tau. J Neurosci 22:133–141
82. Tatebayashi Y, Miyasaka T, Chui DH, Akagi T, Mishima K, Iwasaki
K, Fujiwara M, Tanemura K, Murayama M, Ishiguro K, Planel E,
Sato S, Hashikawa T, Takashima A (2002) Tau Wlament formation
and associative memory deWcit in aged mice expressing mutant
(R406W) human tau. Proc Natl Acad Sci USA 99:13896–13901
83. Terry RD, Masliah E, Salmon DP, Butters N, DeTeresa R, Hill R,
Hansen LA, Katzman R (1991) Physical basis of cognitive altera-
tions in Alzheimer’s disease: synapse loss is the major correlate of
cognitive impairment. Ann Neurol 30:572–580
84. Terwel D, Dewachter I, Van Leuven F (2002) Axonal transport,
tau protein, and neurodegeneration in Alzheimer’s disease. Neuro-
molecular Med 2:151–165
85. Terwel D, Lasrado R, Snauwaert J, Vandeweert E, Van Hae-
sendonck C, Borghgraef P, Van Leuven F (2005) Changed confor-
mation of mutant Tau-P301L underlies the moribund tauopathy,
absent in progressive, nonlethal axonopathy of Tau-4R/2N trans-
genic mice. J Biol Chem 280:3963–3973
86. Thies E, Mandelkow EM (2007) Missorting of tau in neurons
causes degeneration of synapses that can be rescued by the kinase
MARK2/Par-1. J Neurosci 27:2896–2907
87. Tolnay M, Probst A (2003) The neuropathological spectrum of
neurodegenerative tauopathies. IUBMB Life 55:299–305
88. Trojanowski JQ, Smith AB, Huryn D, Lee VM (2005) Microtu-
bule-stabilising drugs for therapy of Alzheimer’s disease and other
neurodegenerative disorders with axonal transport impairments.
Expert Opin Pharmacother 6:683–686
89. Tseng BP, Green KN, Chan JL, Blurton-Jones M, Laferla FM
(2007) Abeta inhibits the proteasome and enhances amyloid and
tau accumulation. Neurobiol Aging. May 31 [Epub ahead of print]
90. Uchihara T (2007) Silver diagnosis in neuropathology: principles,
practice and revised interpretation. Acta Neuropathol (Berl)
113:483–499
91. van Leuven F (2000) Single and multiple transgenic mice as mod-
els for Alzheimer’s disease. Prog Neurobiol 61:305–312
92. van Swieten J, Spillantini M (2007) Hereditary frontotemporal
dementia caused by Tau gene mutations. Brain Pathol 17:63–73
93. Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM
(2007) Stepwise proteolysis liberates tau fragments that nucleate
the Alzheimer-like aggregation of full-length tau in a neuronal cell
model. Proc Natl Acad Sci USA 104:10252–10257
94. Wegiel J, Kuchna I, Nowicki K, Frackowiak J, Mazur-Kolecka B,
Imaki H, Wegiel J, Mehta PD, Silverman WP, Reisberg B, Deleon
M, Wisniewski T, Pirttilla T, Frey H, Lehtimaki T, Kivimaki T,
Visser FE, Kamphorst W, Potempska A, Bolton D, Currie JR,
Miller DL (2007) Intraneuronal Abeta immunoreactivity is not a
predictor of brain amyloidosis-beta or neuroWbrillary degenera-
tion. Acta Neuropathol (Berl) 113:389–402
95. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis
J, Hutton M, Feany MB (2001) Tauopathy in Drosophila: neurode-
generation without neuroWbrillary tangles. Science 293:711–714
96. Wyss-Coray T (2006) InXammation in Alzheimer disease: driving
force, bystander or beneWcial response? Nat Med 12:1005–1015
97. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, Saido
TC, Maeda J, Suhara T, Trojanowski JQ, Lee VM (2007) Synapse
loss and microglial activation precede tangles in a P301S tauopa-
thy mouse model. Neuron 53:337–351
98. Zhang B, Higuchi M, Yoshiyama Y, Ishihara T, Forman MS, Mar-
tinez D, Joyce S, Trojanowski JQ, Lee VM (2004) Retarded ax-
onal transport of R406W mutant tau in transgenic mice with a
neurodegenerative tauopathy. J Neurosci 24:4657–4667
99. Zhang B, Maiti A, Shively S, Lakhani F, McDonald-Jones G,
Bruce J, Lee EB, Xie SX, Joyce S, Li C, Toleikis PM, Trojanowski
JQ, Lee VM (2005) Microtubule-binding drugs oVset tau seques-
tration by stabilizing microtubules and reversing fast axonal trans-
port deWcits in a tauopathy model. Proc Natl Acad Sci USA
102:227–231123
